NCT00833872View on ClinicalTrials.gov

LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions
Psoriasis Vulgaris
Interventions
DRUG

LEO 22811

First-in-man

DRUG

placebo solution

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit Ltd, Leeds

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY